Sanofi India's Q4 FY25 results show a 25% YoY increase in EBITDA to ₹171.90 crore and an EBITDA margin rise to 32.10%. Revenue grew 5% YoY to ₹535.90 crore, with net sales up 4%. However, net profit declined 12.50% YoY to ₹119.50 crore. The launch of Soliqua® contributed to growth, highlighting operational efficiency improvements despite profit challenges.
Sanofi India Limited (SIL) announced strong Q4 2024 results with revenue increasing 10% year-over-year to ₹515 crore and net profit jumping 31% to ₹91.3 crore. The growth was driven by a robust diabetes portfolio, successful launch of Soliqua®, and improved operational efficiency. The company's operating profit rose by 21%. The Board recommended a dividend of ₹117 per equity share for FY2024.
27Feb 25
Sanofi India Reports Mixed Q3 2024 Results with Revenue Growth and Profit Decline
Sanofi India Limited announced its Q3 2024 financial results, showing a 9.8% increase in revenue to ₹5,150 million, but a 33.8% decrease in net profit to ₹913 million. EBITDA grew by 18.5% to ₹1,180 million, with the EBITDA margin improving to 22.98%. Profit Before Tax increased by 14.8% to ₹1,140 million. An exceptional item of ₹80 million was noted, potentially impacting overall profit figures.